Analysis
Anti-obesity medications, IO drug development, AI, personalised/precision medicine, RWE and ADC were rated as the most impactful industry trends for the next 12 months
Survey fielded 16 April to 29 May 2025 Anti-obesity medications
Immuno-oncology (IO) drug development
Artificial intelligence (AI) in pharma value chain Personalised/precision medicine Real world evidence (RWE)
Antibody-drug conjugates (ADC)
Complexity and increasing cost of clinical trials Cell and gene therapy (CGT) Supply chain challenges
mRNA vaccines and therapeutics, including siRNA
Delay in generating product revenue due to pricing and reimbursement process
Biosimilar uptake
Decentralised/virtual clinical trials (DCTs) Radiotherapeutics Others
Microbiome drug development Digital therapeutics (DTx)
2.7
Q: On a scale of 1–5, please rate the anticipated impact of each of the following emerging industry trends on the pharmaceutical industry in the next 12 months (5 indicates the greatest impact, 1 indicates minimal impact). Source: GlobalData, ‘The State of the Biopharmaceutical Industry, 2025 (Mid-Year Update) Edition’
continues to gain momentum, with numerous partnerships and investments aimed at their development and manufacturing. This trend is closely tied to the broader movement towards personalised and precision medicine, which seeks to tailor treatments to individual patient profiles. As the industry pivots towards more targeted therapies, ADCs represent a promising avenue for innovation, despite the inherent challenges in drug development and manufacturing complexities.
The integration of artificial intelligence Artificial intelligence (AI) remains a transformative force within the pharmaceutical value chain. Industry professionals are increasingly recognising AI’s potential to enhance drug discovery, streamline manufacturing processes and improve overall business efficiency. The integration of AI is expected to alleviate some of the research and development challenges that have historically plagued the industry, ultimately accelerating drug development timelines.
The shift towards real-world evidence (RWE)
The growing emphasis on real-world evidence (RWE) trials, leveraging data from digital devices, is another noteworthy trend. Regulatory bodies, including the US FDA and EMA, are playing a pivotal role in promoting the use of RWE, which is becoming increasingly important for both industry and non-industry sponsors. This shift towards RWE
www.worldpharmaceuticals.net
is expected to enhance the understanding of drug efficacy and safety in real-world settings, further informing treatment decisions.
Supply chain challenges and market dynamics
As the industry navigates these trends, supply chain challenges have emerged as a primary concern. A significant proportion of industry professionals now believe that these challenges, alongside pricing and reimbursement issues, will have the most substantial impact on the sector in the second half of 2025. The recent political climate, characterised by potential tariffs and a push for reshoring manufacturing, has intensified focus on supply chain resilience. This all leaves the biopharmaceutical industry facing a confluence of challenges and opportunities. As professionals adapt to the changing landscape, the emphasis on anti-obesity medications, ADCs, AI integration and RWE will likely shape the future of drug development and patient care according to GlobalData’s report. However, the overarching uncertainty stemming from geopolitical tensions, the ever-changing tariff landscape and regulatory changes will require strategic navigation to ensure sustained growth and innovation in the sector. ●
For the full report, visit
www.globaldata.com/store/ report/state-of-biopharmaceutical-industry-analysis
9
3.1 3.1 3.1
3.0
3.5 3.5
3.4 3.9 3.8
3.8 3.8 3.8
3.8
3.7 3.7 3.7
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85
